File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Article: Current management of nasal NK/T-cell lymphoma
Title | Current management of nasal NK/T-cell lymphoma |
---|---|
Authors | |
Issue Date | 2010 |
Publisher | C M P Medica LLC, The Oncology Group. The Journal's web site is located at http://www.karger.com/OCL |
Citation | Oncology, 2010, v. 24 n. 4, p. 352-358 How to Cite? |
Abstract | Nasal natural killer (NK)/T-cell lymphoma--classified as extranodal NK/T-cell lymphoma (ENKTL), nasal type, by the World Health Organization--is a non-Hodgkin lymphoma that is almost always associated with Epstein-Barr virus. Up to 75% of ENKTL cases occur in the upper aerodigestive tract, primarily the nasal cavity. It is the most common type of peripheral T-cell lymphoma in many Asian countries. Histologic diagnosis is essential, and staging consists of bilateral bone marrow biopsy and imaging of the neck, thorax, abdomen, and pelvis. There is a marked dichotomy in treatment and survival between localized and disseminated disease. Since disease incidence is rare even in prevalent areas, experience is limited and most treatment protocols are consensus-guided. ENKTL is both chemosensitive and radiosensitive. Early-stage, localized nasal disease is highly curable with combination therapy, but the optimal dose, combination, and sequence of radiotherapy and chemotherapy are still undefined. For patients with disseminated and extranasal disease, either at initial presentation or at relapse, the prognosis is poor. For disseminated and refractory cases, the 5-year survival rate is below 10%, and better methods of treatment are needed. |
Persistent Identifier | http://hdl.handle.net/10722/209198 |
ISSN | 2023 Impact Factor: 1.8 2023 SCImago Journal Rankings: 0.336 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Au, WY | - |
dc.date.accessioned | 2015-04-09T07:12:12Z | - |
dc.date.available | 2015-04-09T07:12:12Z | - |
dc.date.issued | 2010 | - |
dc.identifier.citation | Oncology, 2010, v. 24 n. 4, p. 352-358 | - |
dc.identifier.issn | 0890-9091 | - |
dc.identifier.uri | http://hdl.handle.net/10722/209198 | - |
dc.description.abstract | Nasal natural killer (NK)/T-cell lymphoma--classified as extranodal NK/T-cell lymphoma (ENKTL), nasal type, by the World Health Organization--is a non-Hodgkin lymphoma that is almost always associated with Epstein-Barr virus. Up to 75% of ENKTL cases occur in the upper aerodigestive tract, primarily the nasal cavity. It is the most common type of peripheral T-cell lymphoma in many Asian countries. Histologic diagnosis is essential, and staging consists of bilateral bone marrow biopsy and imaging of the neck, thorax, abdomen, and pelvis. There is a marked dichotomy in treatment and survival between localized and disseminated disease. Since disease incidence is rare even in prevalent areas, experience is limited and most treatment protocols are consensus-guided. ENKTL is both chemosensitive and radiosensitive. Early-stage, localized nasal disease is highly curable with combination therapy, but the optimal dose, combination, and sequence of radiotherapy and chemotherapy are still undefined. For patients with disseminated and extranasal disease, either at initial presentation or at relapse, the prognosis is poor. For disseminated and refractory cases, the 5-year survival rate is below 10%, and better methods of treatment are needed. | - |
dc.language | eng | - |
dc.publisher | C M P Medica LLC, The Oncology Group. The Journal's web site is located at http://www.karger.com/OCL | - |
dc.relation.ispartof | Oncology | - |
dc.subject.mesh | Adult | - |
dc.subject.mesh | Combined Modality Therapy | - |
dc.subject.mesh | Humans | - |
dc.subject.mesh | Lymphoma, Extranodal NK-T-Cell -- pathology | - |
dc.subject.mesh | Middle Aged | - |
dc.title | Current management of nasal NK/T-cell lymphoma | - |
dc.type | Article | - |
dc.identifier.email | Au, WY: auwing@HKUCC.hku.hk | - |
dc.identifier.hkuros | 180709 | - |
dc.identifier.volume | 24 | - |
dc.identifier.issue | 4 | - |
dc.identifier.spage | 352 | - |
dc.identifier.epage | 358 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 0890-9091 | - |